S&P Futures
5,905.25 -0.75 (-0.01%) Dow Futures
43,559.00 +41.00 (+0.09%) Nasdaq Futures
20,454.25 -29.25 (-0.14%) Russell 2000 Futures
2,293.30 +2.10 (+0.09%) Crude Oil
69.60 +0.38 (+0.55%) Gold
2,741.70 +11.70 (+0.43%)
| Previous Close | 5.0300 |
| Open | 5.0750 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 4.9800 - 5.1500 |
| 52 Week Range | 1.6000 - 5.4500 |
| Volume | |
| Avg. Volume | 22,059 |
| Market Cap | 767.896M |
| Beta (5Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7600 |
| Earnings Date | Aug 30, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.31 |
Insider MonkeyIs Opthea Limited (OPT) the Penny Stock with the Biggest Upside Potential According to Analysts?
In this article, we will look at the 8 Penny Stocks with Biggest Upside Potential According to Analysts. Let’s look at where Opthea Limited (OPT) stands against other penny stocks with the biggest upside potential. Why Are Rate Cuts Good for Small Caps? The Federal Reserve slashed interest rates by a half point in September, kickstarting […]
GlobeNewswireOpthea Files Notice of Annual General Meeting
Megan Baldwin, PhD, MAICD, to retire from the Board and has chosen not to stand for re-election As Founder and Chief Innovation Officer, Dr. Baldwin will continue focusing on advancing Opthea’s innovation agenda MELBOURNE, Australia and PRINCETON, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-relat
